Clarifying Ownership of Clinical Trial IRT Data: Site vs. Sponsor
Stakeholders from across the industry must discuss ownership to ensure effective implementation.
Reviewing FDA’s Latest Guidance on RWD
Roadmap of twists and turns that lie ahead following most recent draft issued in September.
Analysis: FDA’s COVID-19 Accelerated Pathways
Lessons learned from FDA’s current process and proposed alternative review strategies.
Tracking Change in the Global Investigative Site Landscape
New benchmarks uncover a maturing and globally-shifting market.
Darcy Flora, PhD, chief research officer of GRYT Health, a digital oncology company, discusses her career, the company, and drug development.
EMA: A Change in Character as Well as Powers?
Increased public engagement leads recent change in EMA profile.
Pandemic Alters Policies for Drug Development
Lessons learned from COVID-19 vaccine development.
2022 Trends, More of the Same but More
What does 2022 hold for industry?
Applied Clinical Trials December 2021 Issue (PDF)
Click the title above for a link to open the Applied Clinical Trials December 2021 issue in an interactive PDF format.
Assessing Sponsor and CRO Awareness
Improving receptivity and response to the evolving nature of clinical trial patient oversight.
Decentralized vs Digital Clinical Trials: There is a Difference
Considering Patient Burden in Oncology
Implementing new strategies with the use of patient-reported outcomes.
Consequences of Brexit for Clinical Trials in Europe
Higher costs headline list of new challenges faced by CROs and sponsors.
2 Clarke Drive Cranbury, NJ 08512